Gilead Sciences (NASDAQ:GILD) CEO Sells $17,346,000.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel Patrick O’day sold 115,640 shares of the business’s stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $150.00, for a total transaction of $17,346,000.00. Following the transaction, the chief executive officer owned 613,912 shares of the company’s stock, valued at approximately $92,086,800. This represents a 15.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Daniel Patrick O’day also recently made the following trade(s):

• On Wednesday, January 28th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $139.89, for a total transaction of $1,398,900.00.
• On Friday, January 23rd, Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock. The shares were sold at an average price of $135.00, for a total transaction of $15,611,400.00.
• On Monday, December 29th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $124.83, for a total value of $1,248,300.00.
• On Friday, November 28th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $126.54, for a total value of $1,265,400.00.

Gilead Sciences Stock Up 2.1%

NASDAQ:GILD opened at $152.50 on Monday. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $153.13. The stock has a 50-day moving average price of $127.38 and a two-hundred day moving average price of $121.04. The stock has a market cap of $189.20 billion, a price-to-earnings ratio of 23.64, a PEG ratio of 0.80 and a beta of 0.36. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03.

Wall Street Analysts Forecast Growth

Several brokerages have commented on GILD. Scotiabank began coverage on shares of Gilead Sciences in a report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 target price on the stock. Sanford C. Bernstein set a $135.00 price objective on shares of Gilead Sciences and gave the stock an “outperform” rating in a research report on Monday, December 29th. Royal Bank Of Canada boosted their price objective on shares of Gilead Sciences from $100.00 to $103.00 and gave the company a “sector perform” rating in a research report on Tuesday, January 20th. The Goldman Sachs Group increased their target price on Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a report on Thursday, January 8th. Finally, Argus boosted their price target on Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $136.73.

Institutional Investors Weigh In On Gilead Sciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. GoalVest Advisory LLC raised its holdings in Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares in the last quarter. Corundum Trust Company INC acquired a new position in shares of Gilead Sciences during the 3rd quarter worth approximately $26,000. Harbor Asset Planning Inc. bought a new stake in shares of Gilead Sciences during the 2nd quarter worth approximately $27,000. Ares Financial Consulting LLC acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $28,000. Finally, Financial Consulate Inc. grew its stake in shares of Gilead Sciences by 85.8% in the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 109 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.